The radiolabeledbioconjugate, on the other hand, shows a greatly reduced early uptakein the myocardium, indicating that the chelator survives and protectsthe Tl3+ from reduction and dissociation long enough toallow blood clearance (mainly via the kidney), potentially allowingthe opportunity for modest selective uptake in PSMA-expressing tumors,as observed in the in vivo experiments on tumor-bearingmice. The gene discussed is FOLH1; the disease is neoplasm.